AstraZeneca PLC (AZN)vsBioventus Inc (BVS)
AZN
AstraZeneca PLC
$160.17
+2.23%
HEALTHCARE · Cap: $252.33B
BVS
Bioventus Inc
$13.16
+1.39%
HEALTHCARE · Cap: $886.60M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 10447% more annual revenue ($61.37B vs $581.85M). AZN leads profitability with a 17.0% profit margin vs 9.4%. AZN appears more attractively valued with a PEG of 1.28. BVS earns a higher WallStSmart Score of 62/100 (C+).
AZN
Buy60
out of 100
Grade: C+
BVS
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Intrinsic value data unavailable for BVS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Earnings expanding 327.3% YoY
Every $100 of equity generates 24 in profit
Attractively priced relative to earnings
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Expensive relative to growth rate
3.8% revenue growth
Smaller company, higher risk/reward
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : BVS
The strongest argument for BVS centers on EPS Growth, Return on Equity, P/E Ratio.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : BVS
The primary concerns for BVS are PEG Ratio, Revenue Growth, Market Cap.
Key Dynamics to Monitor
AZN profiles as a mature stock while BVS is a value play — different risk/reward profiles.
BVS carries more volatility with a beta of 0.65 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
BVS scores higher overall (62/100 vs 60/100). AZN offers better value entry with a 18.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Bioventus Inc
HEALTHCARE · MEDICAL DEVICES · USA
Bioventus Inc., a medical device company, focuses on developing and commercializing clinical treatments that involve and enhance the body's natural healing process in the United States and internationally. The company is headquartered in Durham, North Carolina.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?